Business Context and Reporting Period
This Form 8-K Current Report was filed by Palisade Bio, Inc. on May 6, 2022, regarding a material definitive agreement entered into on the same date. The Company, incorporated in Delaware and headquartered in Carlsbad, California, is an emerging growth company trading on the Nasdaq Capital Market under the symbol "PALI".
Key Financial Metrics and Transaction Details
The filing details a "Hybrid Offering" consisting of a Registered Direct Offering and a Concurrent Private Placement. Key financial terms include:
- Common Stock Issuance: 3,646,690 shares sold at $0.55 per share.
- Gross Proceeds: Approximately $2.0 million (before fees and expenses).
- Warrant Issuance: Warrants to purchase up to 3,646,690 shares at an exercise price of $0.7105 per share.
- Warrant Terms: Not exercisable for six months; expire five and a half years from issuance.
- Expected Closing: On or about May 10, 2022.
The filing does not provide current revenue, profit, cash flow, margin, debt, or liquidity metrics as this is a transaction report rather than a periodic financial statement.
Material Changes
The primary material change is the dilution of existing shareholders through the issuance of new common stock and warrants. The transaction increases the Company's share count and potential future share count upon warrant exercise. The filing does not provide comparative financial data against prior periods.
Outlook, Risks, and Contingencies
Management Commentary and Use of Proceeds: The filing does not explicitly state the intended use of proceeds in the text provided, though such offerings typically fund operations and clinical development.
Risks and Contingencies:
- Closing Conditions: The transaction is subject to customary closing conditions.
- Registration Obligations: The Company must file a Form S-3 registration statement within 45 days of closing for the resale of warrant shares and use commercially reasonable efforts to have it effective within 181 days.
- Representations: The Purchase Agreements contain representations and warranties that are for the benefit of the parties only and may not reflect current facts or materiality standards viewed by stockholders.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting placement agent fees and offering expenses.
- Confirm the post-offering fully diluted share count including the new shares and warrant shares.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and termination provisions.
- Monitor the filing of the required Form S-3 registration statement for the resale of warrant shares within the 45-day window.
- Check subsequent filings for the specific allocation of the $2.0 million gross proceeds.